# Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

> **NCT00849017** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 309 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide
- **BIOLOGICAL:** albiglutide uptitration
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00849017
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-11
- **Final completion:** 2013-02
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849017, "Safety and Efficacy Study of Albiglutide in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00849017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*